Similar results were observed using combined ALDH and ATM/ATR inhibitors in HR-proficient ovarian cancer cells, substantiating ALDH1A1 and related enzymes as a potential target for therapy [105]. The gene discussed is ALDH1A1; the disease is ovarian carcinoma.